Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neo-Recur: Perioperative PD-1 Antibody in Recurrent HNSCC
NCT07751289Phase 2Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2029
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Event-Free Survival at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07751289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751289.